Amyotrophic Lateral Sclerosis (ALS) is a progressive, neurodegenerative disease that leads to severe disability and loss of voluntary muscle control.

The progression of the disease makes it challenging for ALS patients to visit clinics regularly or participate in clinical trials.

Remote monitoring and the development of digital outcome measures can help overcome these barriers by enabling remote monitoring, participation in clinical trials, and meaningful measurement of outcomes.

Aim of this study

Aparito’s Patient Group Accelerator and ALS Liga Belgium have collaborated to develop digital endpoints that capture the meaningful aspects of health (MAH), concepts of interest (COI), and outcomes to be measured for ALS patients.

We aim to test the usability and clinical utility of these digital outcome measures using the Atom5™ software platform.

Navdeep Sahota1, Elisa Ferrer Mallol1, Dirk De Valck2, Evy Reviers2 and Elin Haf Davies1

1Aparito Limited 2ALS Liga Belgium

Sign up for our newsletter to receive our latest papers, posters and platform updates direct to your inbox!